

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934.

**Date of Report: October 30, 2014**  
(Date of earliest event reported)

---

**Oragenics, Inc.**  
(Exact name of registrant as specified in its charter)

---

**FL**  
(State or other jurisdiction  
of incorporation)

**001-32188**  
(Commission  
File Number)

**59-3410522**  
(IRS Employer  
Identification Number)

**4902 Eisenhower Boulevard, Suite 125**  
**Tampa, FL**  
(Address of principal executive offices)

**33634**  
(Zip Code)

**813-286-7900**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; APPOINTMENT OF CERTAIN OFFICER;  
COMPENSATORY ARRANGEMENT OF CERTAIN OFFICERS**

Effective October 30, 2014 Dr. John Bonfiglio resigned as President, Chief Executive Officer and director of the Company to pursue other opportunities. Dr. Bonfiglio's resignation was not due to any disagreement with the Company on any matter related to its operations, policies or practices. The Company expects to enter into a Separation, Severance and Release Agreement with Dr. Bonfiglio providing him with the benefits under his employment agreement with the Company for a separation without cause.

The Board of Directors will provide direction to the Company with Dr. Frederick Telling acting as its liaison to management. In addition, the Company's Chief Financial Officer, Mr. Michael Sullivan, will serve as the interim principal executive officer of the Company while the Board conducts a search for a new President and Chief Executive Officer to succeed Dr. Bonfiglio. A copy of the October 30, 2014 press release announcing the Change in Management and Board of Directors is attached to this report as Exhibit 99.1 and is incorporated herein by reference.

In connection with Mr. Sullivan's undertaking additional duties as interim Principal Executive Officer of the Company, the Board approved an award to Mr. Sullivan of an option to purchase 25,000 shares of Company common stock under the Company's 2012 Equity Incentive Plan. The option time vests and becomes exercisable in six months and the exercise price is \$0.86 per share, the closing price on the date of the grant. The stock option is subject to earlier vesting upon a change in control of the Company.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press Release dated October 30, 2014

---

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 30<sup>th</sup> day of October, 2014.

**ORAGENICS, INC.**  
**(Registrant)**

BY: /s/ Michael Sullivan  
Michael Sullivan  
Chief Financial Officer



## Oragenics, Inc. Announces Change in Management and Board of Directors

### For Immediate Release

**TAMPA, FL –October 30, 2014** – Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT – OGEN) has announced that on October 30, 2014, Dr. John Bonfiglio resigned as Chief Executive Officer, President and director of Oragenics, Inc. to pursue other opportunities.

During the interim period before a new CEO is hired, the Board of Directors will provide direction to the Company, with Dr. Frederick Telling acting as its liaison with management. Mr. Sullivan, the Company's current CFO, will serve as the Company's interim principal executive officer to address the vacancy created by Dr. Bonfiglio's resignation. The Board of Directors has begun the process of finding a permanent successor to Dr. Bonfiglio.

After his resignation, Dr. Bonfiglio stated "I am pleased to have had the opportunity to be of service to the Company and I remain optimistic about its future and the prospects for lantibiotic development." Speaking for the Board of Directors, Dr. Telling stated: "Through John's efforts the Company successfully developed a partnership with Intrexon and obtained substantial financing to advance its lantibiotic development and Company operations, which has positioned the Company for future growth. I want to thank Dr. Bonfiglio for his efforts on behalf of the Company and am confident he will be successful in his future endeavors."

### **About Oragenics, Inc.**

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation Inc. (XON), a synthetic biology company. The collaborations will allow Oragenics access to Intrexon's proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in more than 13 countries worldwide.

For more information about Oragenics, visit [www.oragenics.com](http://www.oragenics.com). Follow Oragenics on [Facebook](#) and [Twitter](#).

**Safe Harbor Statement:** *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's current views with respect to future events and performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in the filings of Intrexon and Oragenics with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.*

---

**Orogenics Corporate Contact****Michael Sullivan**

Chief Financial Officer

Orogenics, Inc.

4902 Eisenhower Drive, Suite 125

Tampa, FL 33634

Tel: 813-286-7900

[msullivan@orogenics.com](mailto:msullivan@orogenics.com)**Investor / Media Contacts****Stephanie Carrington / Aaron Estrada**

The Ruth Group

Tel: 646-536-7017/7028

[scarrington@theruthgroup.com](mailto:scarrington@theruthgroup.com) / [aestrada@theruthgroup.com](mailto:aestrada@theruthgroup.com)